Document and Entity Information Entity Addresses [Table] Class of Stock [Axis] Class of Stock [Domain] Common Stock [Member] Ordinary Shares ADR [Member] ADS Entity Addresses [Line Items] Document and Entity Information Document Type Document Annual Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address State Or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction Entity Shell Company Entity Public Float Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Auditor Name Auditor Location Auditor Firm ID Consolidated Balance Sheets Statement [Table] Statement [Line Items] Statement Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash balance Short-Term Investments Investments Prepaid Expense and Other Assets, Current Less: Short-term portion Prepaid expenses and other current assets Assets, Current Total current assets Prepaid Expense, Noncurrent Prepaid expenses - long term Long-term portion Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total Interest Payable, Current Accrued interest and financing expense Other Liabilities, Current Less: Short-term portion Due to officers - short term Other Liability, Current, Related Party, Type [Extensible Enumeration] Other liability, current, related party, type extensible enumeration Liabilities, Current Total current liabilities Other Liabilities, Noncurrent Long-term portion Due to officers - long term Other Liability, Noncurrent, Related Party, Type [Extensible Enumeration] Other liability, noncurrent, related party, type extensible enumeration Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies Stockholders' Equity Attributable to Parent [Abstract] Shareholders' equity: Common Stock, Value, Issued Ordinary shares, no par value per share, 5,000,000,000 and 100,000,000 ordinary shares authorized at December 31, 2025 and December 31, 2024, respectively - 52,441,360 (1,498,325 ADS's) ordinary shares issued and outstanding at December 31, 2025 and 8,948,164 (255,661 ADS's) ordinary shares issued and outstanding at December 31, 2024 Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Additional Paid in Capital Additional paid in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance at end of year Balance at beginning of year Total shareholders' equity Liabilities and Equity Total liabilities and shareholders' equity Common Stock, Par or Stated Value Per Share Ordinary shares, par value Common Stock, Shares Authorized Ordinary shares, shares authorized Common Stock, Shares, Issued Ordinary shares, shares issued Common Stock, Shares, Outstanding Balance at ending of year (in shares) Balance at beginning of year (in shares) Ordinary shares, shares outstanding Consolidated Statements of Operations and Other Comprehensive Loss Operating Expenses [Abstract] Operating expenses Selling, General and Administrative Expense General and administrative Research and Development Expense Research and development Total research and development expenses Operating Costs and Expenses Total operating expenses Other (income) and expenses Unrealized Gain (Loss) on Derivatives Unrealized gain Investment Income, Interest and Dividend Realized and accrued interest income Nonoperating Income (Expense) Total other income Net loss Net loss Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive loss Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation Foreign currency adjustment Other Comprehensive Income (Loss), Net of Tax Total other comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Earnings Per Share, Basic and Diluted [Abstract] Loss per ADS Earnings Per Share, Basic Basic Earnings Per Share, Diluted Fully-diluted Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average number of ADS's outstanding Weighted Average Number of Shares Outstanding, Basic Basic Weighted Average Number of Shares Outstanding, Diluted Fully-diluted Consolidated Statements of Shareholders' Equity Equity Components [Axis] Equity Component [Domain] Additional Paid-in Capital [Member] Additional Paid in Capital Retained Earnings [Member] Accumulated Deficit AOCI Attributable to Parent [Member] Accumulated other comprehensive loss Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents information pertaining to series warrants. Series Warrants [Member] Warrants Represents the information related to pre funded warrants. Pre Funded Warrants [Member] Pre-funded warrants Pre-Funded Warrants APIC, Share-based Payment Arrangement, Increase for Cost Recognition Stock based compensation Stock Issued During Period, Value, New Issues Issuance of ADS and Pre-Funded Warrants, net Ordinary warrants Stock Issued During Period, Shares, New Issues Issuance of ADS and Pre-Funded Warrants, net (in shares) Ordinary shares Value of stock issued as a result of the exercise of warrants. Stock Issued During Period, Value, Warrants Exercised Exercise Shares of stock issued as a result of the exercise of warrants. Stock Issued During Period, Shares, Exercise of Warrants Exercise (in shares) Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows used in operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Share-based Payment Arrangement, Noncash Expense Stock based compensation Amortization of Intangible Assets Amortization of intangibles Amortization expense of intangibles Amount of accrued interest, realized and unrealized gain (loss) on investments. Investments, Accrued Interest, Realized And Unrealized Gain (Loss) Realized and unrealized gain and accrued interest on investments Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities: Increase (Decrease) in Accounts Payable and Accrued Expenses Increase (decrease) in accounts payable and accrued expenses Increase (Decrease) in Prepaid Expense Decrease in prepaid expenses and other assets Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows provided by investing activities: Payments to Acquire Investments Purchase of investments Proceeds from Sale, Maturity and Collection of Investments Proceeds from redemption of investments Net Cash Provided by (Used in) Investing Activities Net cash used by investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows (used in) provided by financing activities: Repayments of Related Party Debt Payment of amounts due to officers Non-bearing interest indebtedness Proceeds from Issuance of Common Stock Proceeds from sale of equity securities, net Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Effect of foreign exchange rate on changes on cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Net change in cash and cash equivalents: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents - end of year Cash and cash equivalents - beginning of year Supplemental Cash Flow Information [Abstract] Supplemental information - Non cash items: Amount of offering expenses associated with warrant modification. Offering Expenses Associated with Warrant Modification Offering expenses associated with warrant modification Amount of accrued offering expense included in additional paid in capital. Accrued Offering Expenses included In Additional Paid In Capital Accrued offering expenses included in additional paid in capital ORGANIZATION AND BUSINESS Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] ORGANIZATION AND BUSINESS No definition available. LIQUIDITY RISKS AND OTHER UNCERTAINTIES Substantial Doubt about Going Concern [Text Block] LIQUIDITY RISKS AND OTHER UNCERTAINTIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES ACCRUED INTEREST AND FINANCING EXPENSE The entire disclosure pertaining to accrued interest and financing expense. Accrued Interest and Financing Expense[Text Block] ACCRUED INTEREST AND FINANCING EXPENSE FAIR VALUE OF FINANCIAL INSTRUMENTS Fair Value Disclosures [Text Block] FAIR VALUE OF FINANCIAL INSTRUMENTS STOCK BASED COMPENSATION Share-based Payment Arrangement [Text Block] STOCK BASED COMPENSATION PREPAID EXPENSES AND OTHER CURRENT ASSETS The entire disclosure for current and non-current prepaid expenses. Prepaid Expense Disclosure Text Block PREPAID EXPENSES AND OTHER CURRENT ASSETS ACCRUED EXPENSES Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] ACCRUED EXPENSES IN-LICENSED TECHNOLOGY Asset Acquisition [Text Block] IN-LICENSED TECHNOLOGY INTANGIBLE ASSETS Intangible Assets Disclosure [Text Block] INTANGIBLE ASSETS RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] RELATED PARTY TRANSACTIONS RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS Commitments Disclosure [Text Block] RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS SHAREHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] SHAREHOLDERS' EQUITY INCOME TAXES Income Tax Disclosure [Text Block] INCOME TAXES CONTINGENCIES Contingencies Disclosure [Text Block] CONTINGENCIES No definition available. LICENSE AGREEMENTS The entire disclosure for license agreements. License Agreements [Disclosure Text Block] LICENSE AGREEMENTS Basis of Accounting, Policy [Policy Text Block] Basis of Presentation: Consolidation, Policy [Policy Text Block] Principles of Consolidation: Use of Estimates, Policy [Policy Text Block] Use of estimates: Cash and Cash Equivalents, Policy [Policy Text Block] Cash and cash equivalents: Disclosure of accounting policy for warrants. Warrants Policy [Policy Text Block] Warrants: Investment, Policy [Policy Text Block] Investments: Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Long-lived assets: Segment Reporting, Policy [Policy Text Block] Operating Segment: Research and Development Expense, Policy [Policy Text Block] Research and development: Income Tax, Policy [Policy Text Block] Income taxes: Share-based Payment Arrangement [Policy Text Block] Stock based compensation: Fair Value Measurement, Policy [Policy Text Block] Fair value of financial instruments: Earnings Per Share, Policy [Policy Text Block] Earnings (loss) per share: New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements: Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of research and development expenses Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] FAIR VALUE OF FINANCIAL INSTRUMENTS Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of assets and liabilities measured at fair value on a recurring basis Share-based Payment Arrangement, Option, Activity [Table Text Block] Summary of stock-based activities under the Amended & 2025 Plans Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of weighted average assumptions of stock options granted valued using the Black-Scholes option-pricing model Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Schedule of Prepaid expenses and other current assets Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of intangible assets Schedule of Related Party Transactions [Table Text Block] Schedule of amounts due to officers Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of warrants outstanding Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of U.S. and foreign loss before income taxes Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of reconciliation between effective tax and tax computed by applying the U.S. federal income tax rate Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of deferred tax assets and liabilities Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] ORGANIZATION AND BUSINESS SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Stockholders' Equity Note, Stock Split, Conversion Ratio Reverse stock split Stock split Represents the number of clinical sites. Number Of Clinical Sites Number of clinical sites Debt Securities, Trading, and Equity Securities, FV-NI U.S. treasury bills Cash Equivalents, at Carrying Value Cash balance Duration of investments maturity term. Investments Maturity Term Maturity term Finite-Lived Intangible Asset, Useful Life Intangible assets, useful life Goodwill and Intangible Asset Impairment Impairment loss measurement Unrecognized Tax Benefits Schedule of Segment Reporting Information, by Segment [Table] Segments [Axis] Segments [Domain] Represents information pertaining to single reportable segment. Single reportable segment Segment Reporting Information [Line Items] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Number of Reportable Segments Number of reportable segments Number of Operating Segments Number of operating segments Amount of expense for research and development pursuant to external clinical development. Research and Development Expense, External Clinical Development External clinical development expenses Amount of expense for research and development pursuant to personnel related and stock-based compensation. Research and Development Expense, Personnel Related And Stock Based Compensation Personnel related and stock-based compensation Other Research and Development Expense Other research and development expenses Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] This member represents outstanding warrants. Outstanding Warrants [Member] Outstanding warrants Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of prefunded warrants. Incremental Common Shares Attributable To Dilutive Effect Of Pre Funded Warrants Unexercised prefunded warrants Schedule of Long-term Debt Instruments [Table] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Convertible Debt Convertible Notes issued in 2020. Convertible notes 2020 Convertible notes 2020 Convertible Notes Warrants, Common Stock. Convertible Notes Warrants, Common Stock Convertible notes warrants, common stock Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ACCRUED INTEREST AND FINANCING EXPENSE[Line Items] ACCRUED INTEREST AND FINANCING EXPENSE Stock Issued During Period, Shares, Conversion of Convertible Securities Shares issued upon conversion Represents the number of noteholders who received consideration. Convertible Notes Payable, Number of Noteholders Who Received Consideration Number of notes holders who received consideration Represents the number of noteholders. Convertible Notes Payable, Number of Noteholders Total number of notes holders Represents the number of remaining noteholders who received consideration. Convertible Notes Payable, Number Of Remaining Noteholders Receive Consideration Number of remaining noteholders Interest Expense, Debt, Excluding Amortization Interest expense Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Recurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] FAIR VALUE OF FINANCIAL INSTRUMENTS Investments, Fair Value Disclosure US Treasury Bills and Notes Cash and Cash Equivalents, Fair Value Disclosure Mutual Funds Assets, Fair Value Disclosure Total Assets Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Represents information pertaining to the amended and restated equity incentive Plan (the "Amended Plan"). Amended Plan [Member] Amended Plan Represents information pertaining to 2025 equity incentive plan. Equity Incentive Plan 2025 [Member] 2025 Plan Share-based Compensation Arrangement by Share-based Payment Award [Line Items] STOCK BASED COMPENSATION Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Percentage of ordinary shares reserved for issuance Common Stock, Capital Shares Reserved for Future Issuance Number of ordinary shares reserved for future issuance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of options outstanding at end of period (in shares) Number of options outstanding at beginning of period (in shares) Number of options outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Number of shares available for issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Number of shares authorized Maximum annual increase in shares authorized for issuance under share based payment arrangement expressed as percentage of shares issued and outstanding. Share-Based Compensation Arrangement By Share-Based Payment Award, Authorized, Maximum Annual Increase As Percentage Of Issued And Outstanding Percentage of ordinary shares issued and outstanding Represents information pertaining to the amended and restated equity incentive Plan (the "Amended Plan") and 2025 equity incentive plan. Amended And Restated Equity Incentive Plan And Equity Incentive Plan 2025 [Member] Amended & 2025 Plans Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] ADS Underlying Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted (in share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Exercisable options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at the end of the period (in dollars per share) Outstanding at beginning of the period (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Canceled (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable options (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted Average Contractual Terms Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Exercisable options (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Intrinsic value of outstanding options Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected life of options in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price Exercise Price Share Price Fair value of stock The estimated fair value of option assumption that is used in valuing an option on its own shares. Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Estimated Fair Value of Option Estimate fair value of option Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Statement Location [Axis] Income Statement Location [Domain] Research and Development Expense [Member] Research and development expense General and Administrative Expense General and administrative expenses Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] STOCK BASED COMPENSATION Share-based Payment Arrangement, Expense Stock based compensation expense Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized stock compensation expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unrecognized stock compensation expense expected to be recognized over the remaining weighted average service period Amount of asset related to research and development costs paid in advance that provide future economic benefits. Prepaid Research And Development Costs Prepaid R&D costs Amount of asset related to consideration paid in advance for insurance that provides future economic benefits. Prepaid Insurance, Current and Noncurrent Prepaid insurance Prepaid Expense Prepaid expense Prepaid Expense and Other Assets Total Carrying value as of the balance sheet date of obligations incurred through that date and payable for research contract expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Research Contract Expense Current Research contract expenses Accrued research and development expense Accrued Salaries, Current Payroll Accrued Payroll Taxes, Current Payroll taxes Carrying amount as of the balance sheet date for cost to be paid as special or contractual termination benefits provided to current employees who are involuntarily terminated. Accrued Severance Costs Accrued severance Accrued Professional Fees, Current Professional fees Other Accrued Liabilities, Current Other expenses Asset Acquisition [Table] Asset Acquisition [Axis] Asset Acquisition [Domain] This member stands for skinvisible license agreement. Skinvisible License Agreement [Member] Skinvisible Licensing Agreement Asset Acquisition [Line Items] IN-LICENSED TECHNOLOGY Asset Acquisition, Consideration Transferred License fee Represents the percentage of revenues to be paid under asset acquisition. Asset Acquisition, Percentage of Revenues to be Paid Percentage of revenues to be paid Asset Acquisition, Contingent Consideration, Liability Amount of payment to be made Amount of milestone or royalty obligations payable. Milestone Payments Or Royalty Obligations Payable Milestone or royalty obligations due Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Licensing Agreements [Member] Technology license - Skinvisible Finite-Lived Intangible Assets [Line Items] INTANGIBLE ASSETS Finite-Lived Intangible Assets, Gross Total cost Finite-Lived Intangible Assets, Accumulated Amortization Accumulated amortization Finite-Lived Intangible Assets, Net Net book value Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Expected amortization expense Finite-Lived Intangible Asset, Expected Amortization, Year One 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four 2029 Schedule of Related Party Transactions, by Related Party [Table] Counterparty Name [Axis] Counterparty Name [Domain] Represents the information pertaining to Dr. Myers. Dr. Myers [Member] Dr. Myers Represents the information pertaining to Ms. Carter. Ms. Carter [Member] Ms. Carter Related Party Transaction [Line Items] RELATED PARTY TRANSACTIONS The amount of monthly payment to related party. Payment to Related Party Per Month Monthly payment amount Other Liabilities Salaries and other compensation Outstanding indebtedness Other Liability, Related Party [Extensible Enumeration] Long-term Purchase Commitment [Table] Represents information pertaining to Therapeutics Inc. Therapeutics Inc. [Member] Therapeutics Inc. Represents Netherton Syndrome. Netherton Syndrome [Member] Netherton Syndrome Represents information pertaining to Scleroderma. Scleroderma [Member] Scleroderma Represents information relating to the school of pharmacy at UCC. The School Of Pharmacy At UCC [Member] The School of Pharmacy at UCC Long-term Purchase Commitment [Line Items] RESEARCH, CONSULTING AGREEMENTS AND COMMITMENTS Period of between signing and termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Agreement, Initial Term Initial term Period of between written notice of termination and actual termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Agreement Written Termination Notice Written termination notice period The aggregate amount of fee per consulting or service agreement. Consulting or Service Agreement, Agreed Amount Total amount of agreement The amount of credit received for the prior research and development expenses incurred. Credit Of Prior Research And Development Expense Credit of prior expenses incurred The maximum liability for the entity in relation to the funding for the research agreement entered into. Research Agreement, Maximum Funding Amount Maximum funding amount Long-Term Purchase Commitment, Period Commitment period Schedule of Stock by Class [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Represents the information related to alumni purchase agreement Alumni Purchase Agreement [Member] Alumni Purchase Agreement Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum [Member] Maximum Sale of Stock [Axis] Sale of Stock [Domain] Represents information pertaining to 2024 public offering. Public Offering 2024 [Member] 2024 Public Offering Represents information pertaining to March 2024 public offering. March 2024 Offering March 2024 Offering Represents information pertaining to December 2024 public offering. December 2024 Offering December 2024 Offering Private Placement October 2025 Private Placement Represents information pertaining to March 2024 Pre-funded warrants. March 2024 Prefunded Warrants [Member] March 2024 Pre-Funded Warrants Represents information pertaining to Series D Warrants. Series D Warrants [Member] Series D Warrants Represents information pertaining to Series E Warrants. Series E Warrants [Member] Series E Warrants Represents information pertaining toAmerican depositary shares and accompanying Series F warrants and Series G warrants. American Depositary Shares And Accompanying December 2024 Warrants [Member] American Depositary Shares and Accompanying December 2024 Warrants Represents information pertaining to March 2024 Pre-funded warrants and accompanying Series D warrants and Series E warrants. March 2024 Prefunded Warrants And Accompanying March 2024 Warrants [Member] March 2024 Pre-Funded Warrants and Accompanying Series D Warrants and Series E Warrants Represents information pertaining to existing warrants which are modified. Existing Modified Warrants [Member] Existing modified warrants Represents information pertaining to December 2024 Pre-funded warrants. December 2024 Prefunded Warrants [Member] December 2024 Prefunded Warrants Represents information pertaining to March 2024 Pre-funded warrants and accompanying Series F warrants and Series G warrants. December 2024 Prefunded Warrants And Accompanying December 2024 Warrants [Member] December 2024 Prefunded Warrants and Accompanying December 2024 Warrants Represents information pertaining to Series F warrants and Series G warrants. December 2024 Warrants [Member] December 2024 Warrants Represents information pertaining to Series F Warrants. Series F Warrants [Member] Series F Warrants Represents information pertaining to Series G Warrants. Series G Warrants [Member] Series G Warrants Represents information pertaining to October 2025 Pre-Funded Warrants. October 2025 Pre-Funded Warrants [Member] October 2025 Pre-Funded Warrants Represents information pertaining to Series H, Series I, Series J, and Series K warrants. October 2025 Warrants [Member] October 2025 Ordinary Warrants Represents information pertaining to Series H Warrants. Series H Warrants [Member] Series H Warrants Represents information pertaining to Series I Warrants. Series I Warrants [Member] Series I Warrants Represents the information related to Series I, tranche one warrants. Series I, Tranche One Warrants [Member] Series I, Tranche one warrants Represents the information related to Series I, tranche two warrants. Series I, Tranche Two Warrants [Member] Series I, Tranche two warrants Represents information pertaining to Series J Warrants. Series J Warrants [Member] Series J Warrants Represents information pertaining to Series K Warrants. Series K Warrants [Member] Series K Warrants Title of Individual [Axis] Title of Individual [Domain] Person with designation of officer and person serving on board of directors. Officers And Directors [Member] Officers and Directors Director [Member] Directors Scenario [Axis] Scenario [Domain] Represents the information related to warrants exercisable term from closing date. Warrants Exercisable Term From Closing Date [Member] Warrants exercisable term from closing date Represents the information related to public announcement for baseline controlled pivotal studies. Public Announcement For Baseline controlled Pivotal Studies [Member] Public announcement for baseline controlled pivotal studies Represents the information related to public announcement for monotherapy pivotal trial. Public Announcement For Monotherapy Pivotal Trial [Member] Public announcement for monotherapy pivotal trial Represents the information related to public announcement for adjuvant pivotal trial. Public Announcement For Adjuvant Pivotal Trial [Member] Public announcement for adjuvant pivotal trial Represents the information related to public announcement for accelerated or traditional approval for treatment. Public Announcement For Accelerated Or Traditional Approval For Treatment [Member] Public announcement for accelerated or traditional approval for treatment Represents the information related to public announcement for sale of priority review voucher. Public Announcement For Sale Of Priority Review Voucher [Member] Public announcement for sale of priority review voucher Equity, Class of Treasury Stock [Line Items] SHAREHOLDERS' EQUITY Shares Issued, Price Per Share Price per share, shares issued Sale of Stock, Consideration Received Per Transaction Proceeds from sale of equity securities, gross Class of Warrant or Right, Number of Securities Called by Warrants or Rights Shares warrants may purchase Number of warrants or rights exercised during the period. Class of Warrant or Right, Exercised Warrants exercised (in shares) Number of warrants or rights exercised Number of warrants issued during the period. Class Of Warrant Or Right Issued Warrants granted (in shares) Proceeds from Warrant Exercises Warrants gross proceeds The of number of most recent years prior to the current period the income of which limits the distribution. Number Of Years Income For Distribution Limit Number of years of income that limits distribution The maximum period of between date of financial statements and distribution, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Date Of Financial Statements And Distribution Period Maximum Maximum period between date of financial statements and distribution date Payments of Stock Issuance Costs Stock offering expense The floor price per share. Floor Price Floor price The minimum commitment amount for which purchase notices agreed to be issued. Minimum Commitment Amount For Which Purchase Notices Agreed To Be Issued Minimum commitment amount The maximum value of commitment securities that can be issued at the times set forth under the agreement. Maximum Commitment Securities Value At Times Set Forth Under Agreement Maximum commitment securities value The maximum commitment amount related to right to sell newly issued ordinary shares that are represented by ADS. Maximum Commitment Amount Commitment amount Represents the threshold period agreed not to sell any ADSs from the closing date of the 2024 Offering. Threshold Period Agreed Not To Sell Any AdsS From Closing Date Of Offering Purchase agreement period Number of ordinary shares for each American Depositary Shares. Number Of Ordinary Shares For Each American Depositary Shares Number of ordinary shares for each ADS The combined public offering price. Combined Public Offering Price Combined public offering price Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Warrants and Rights Outstanding, Term Warrants, term Represents the threshold period for not to enter into an agreement to effect a variable rate transaction, after the closing date of the Offering. Threshold Period for Not to Enter Into an Agreement to Effect a Variable Rate Transaction, After the Closing Date of the Offering Threshold period for not to enter into an agreement to effect a variable rate transaction, after the closing date of the Offering Represents the threshold period for not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any ADSs, ordinary shares or ordinary share equivalents, after the closing date of the Offering Threshold Period for Not to Issue, Enter Into Any Agreement to Issue or Announce the Issuance or Proposed Issuance of Any ADSs, After the Closing Date of the Offering Threshold period for not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any ADSs, ordinary shares or ordinary share equivalents, after the closing date of the Offering Minimum threshold percentage of outstanding shares taken for consideration for non-exercise of warrants. Minimum Threshold Percentage Of Outstanding Shares For Non Exercise Of Warrants Percentage of ordinary Shares outstanding Percentage of warrants that are exercisable. Warrants Exercisable Percentage Warrants exercisable percentage Sale of Stock, Consideration Received on Transaction Net proceeds Percentage of aggregate gross proceeds paid as placement agent fees by the entity. Placement Agent Fees Percentage Of Aggregate Gross Proceeds Percentage of gross proceeds of private placement Maximum payment of legal fees and out of pocket expenses paid by the entity to placement agent. Maximum Payment Of Legal Fees And Out Of Pocket Expenses To Placement Agent Legal fees and out of pocket expenses Represents information relating to the prior warrants. Prior Warrants [Member] Prior warrants Minimum [Member] Minimum Class of Stock [Line Items] SHAREHOLDERS' EQUITY Class of Warrant or Right, Outstanding Warrants outstanding and exercisable, end (in shares) Warrants outstanding and exercisable, beginning (in shares) Number of warrants or rights terminated during the period. Class of Warrant or Right, Terminated Warrants terminated (in shares) Weighted average exercise price of warrants outstanding during the period. Class Of Warrant Or Right, Weighted Average Exercise Price, Outstanding Warrants weighted average exercise price outstanding and exercisable, end (in dollars per share) Warrants weighted average exercise price outstanding and exercisable, beginning (in dollars per share) Weighted average exercise price of warrants issued during the period. Class Of Warrant Or Right, Weighted Average Exercise Price, Issued Warrants weighted average exercise price granted (in dollars per share) Weighted average exercise price of warrants exercised during the period. Class Of Warrant Or Right, Weighted Average Exercise Price, Exercised Warrants weighted average exercise price exercised (in dollars per share) Weighted average exercise price of warrants terminated during the period. Class Of Warrant Or Right, Weighted Average Exercise Price, Terminated Warrants weighted average exercise price terminated (in dollars per share) Income (Loss) from Continuing Operations before Income Taxes, Domestic United States Income (Loss) from Continuing Operations before Income Taxes, Foreign Foreign Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Book earnings (loss) before taxes Income before income taxes Effective Income Tax Rate Reconciliation [Table] Income Tax Authority [Axis] Income Tax Authority [Domain] Domestic Tax Authority [Member] Federal UNITED STATES U.S Foreign Tax Jurisdiction [Member] Foreign Tax Jurisdiction Effective Income Tax Rate Reconciliation [Line Items] INCOME TAXES Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Amount Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Federal Statutory Rate U.S. Federal Statutory Tax Rate Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount State Income Tax State & Local Income Taxes, Net of Federal Income Tax Effect Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Change in Valuation Allowance Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Other Differential Effective Income Tax Rate Reconciliation, Tax Credit, Amount [Abstract] Tax Credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Research and development tax credits Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount [Abstract] Nontaxable or Nondeductible Items Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expense related to executive compensation. Effective Income Tax Rate Reconciliation, Nondeductible Executive Compensation Expense, Amount IRC 162(m) Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expense or non taxable income. Effective Income Tax Rate Reconciliation, Nondeductible Expense Or Tax Exempt Income, Other, Amount Other Income Tax Expense (Benefit) Effective Tax Effective Income Tax Rate Reconciliation, Percent [Abstract] Percentage Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Federal income tax rate (as a percent) U.S. Federal Statutory Tax Rate Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent State & Local Income Taxes, Net of Federal Income Tax Effect Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Change in Valuation Allowance Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Other Differential Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent Effect of Cross-Border Tax Laws Effective Income Tax Rate Reconciliation, Tax Credit, Percent [Abstract] Tax Credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Research and development tax credits Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent [Abstract] Nontaxable or Nondeductible Items Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses related to executive compensation. Effective Income Tax Rate Reconciliation, Nondeductible Executive Compensation Expense, Percent IRC 162(m) Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expense or non taxable income. Effective Income Tax Rate Reconciliation, Nondeductible Expense Or Tax Exempt Income, Other, Percent Other Effective Income Tax Rate Reconciliation, Tax Contingency, Percent Changes in Unrecognized Tax Benefits Effective Income Tax Rate Reconciliation, Percent Effective tax rate (as a percent) Disclosure of information about income taxes. INCOME TAXES [Table] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. INCOME TAXES [Line Items] INCOME TAXES Components of Deferred Tax Assets [Abstract] Deferred tax assets: Deferred Tax Assets, Goodwill and Intangible Assets Intangible Assets Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Accrued Expenses Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Stock Based Compensation Deferred Tax Assets, in Process Research and Development Research & Development Deferred Tax Assets, Unrealized Currency Losses Unrealized Exchange Gain/Loss Deferred Tax Assets, Operating Loss Carryforwards Net operating losses Deferred Tax Assets, Operating Loss Carryforwards, Foreign Foreign Operating Loss Deferred Tax Assets, Tax Credit Carryforwards, Research R&D Credits Deferred Tax Assets, Gross Total gross deferred tax assets/(liabilities) Deferred Tax Assets, Valuation Allowance Less valuation allowance Deferred Tax Assets, Net of Valuation Allowance Net deferred tax assets/(liabilities) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Increase in valuation allowance Operating Loss Carryforwards Net operating loss carryforward Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws that are not subject to expiration dates. Operating Loss Carryforwards, Not Subject to Expiration Federal net operating loss carryforwards Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalization of research and development costs in accordance with IRC 174. Deferred Tax Asset, Capitalization of Research and Development Costs Deferred tax asset related to TCJA Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Permanent Differences Amount of increase (decrease) between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expenses. Effective Income Tax Rate Reconciliation, Research and Development, Amount Research and Development Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount State rate change Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred true up amount. Effective Income Tax Rate Reconciliation, Deferred True Up, Amount Deferred True Up Number of new license and supply agreements entered during the period. Number Of License And Supply Agreements Entered Number of license and supply agreements entered Royalty Income, Nonoperating Royalty revenues